We recently hosted Piramal Pharma Ltd at the JM Financial Promoter Conference, represented by Nandini Piramal (promoter and chairperson) and Peter DeYoung (CEO). The management discussed the company’s recent performance and future growth strategy across its core businesses. The company has outlined an ambitious roadmap to nearly double revenues in key segments by FY30, driven by steady organic growth, margin expansion, and increased operating leverage. The management also highlighted the broader industry funding environment, noting its critical importance to sustaining growth. Below are the key takeaways